Analysts Anticipate Evoke Pharma Inc (NASDAQ:EVOK) to Post -$0.06 Earnings Per Share

Share on StockTwits

Equities analysts expect Evoke Pharma Inc (NASDAQ:EVOK) to report earnings of ($0.06) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings per share of ($0.10) during the same quarter last year, which would suggest a positive year over year growth rate of 40%. The company is expected to issue its next earnings results on Wednesday, March 4th.

On average, analysts expect that Evoke Pharma will report full-year earnings of ($0.31) per share for the current year. For the next year, analysts expect that the business will post earnings of ($0.19) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02.

A number of research firms recently commented on EVOK. Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Wednesday. HC Wainwright reaffirmed a “hold” rating on shares of Evoke Pharma in a report on Monday, December 2nd.

Shares of NASDAQ:EVOK traded up $0.05 during mid-day trading on Friday, reaching $1.66. The company had a trading volume of 307,898 shares, compared to its average volume of 555,047. The firm has a market cap of $40.23 million, a price-to-earnings ratio of -3.61 and a beta of 1.86. The company’s 50-day moving average price is $1.14 and its 200-day moving average price is $0.91. Evoke Pharma has a one year low of $0.50 and a one year high of $3.26.

An institutional investor recently bought a new position in Evoke Pharma stock. Citadel Advisors LLC purchased a new position in Evoke Pharma Inc (NASDAQ:EVOK) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 59,047 shares of the specialty pharmaceutical company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned 0.25% of Evoke Pharma at the end of the most recent quarter. Hedge funds and other institutional investors own 6.57% of the company’s stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Featured Article: Are we seeing the beginning of a new bubble?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

QuickLogic  Downgraded by Zacks Investment Research to Sell
QuickLogic Downgraded by Zacks Investment Research to Sell
Regeneron Pharmaceuticals  Upgraded to “Buy” by BidaskClub
Regeneron Pharmaceuticals Upgraded to “Buy” by BidaskClub
Proofpoint  Raised to “Buy” at BidaskClub
Proofpoint Raised to “Buy” at BidaskClub
Omeros  Upgraded at BidaskClub
Omeros Upgraded at BidaskClub
360 Finance  Rating Increased to Buy at ValuEngine
360 Finance Rating Increased to Buy at ValuEngine
Kiniksa Pharmaceuticals  Downgraded by Zacks Investment Research to “Sell”
Kiniksa Pharmaceuticals Downgraded by Zacks Investment Research to “Sell”


 
© 2006-2020 Zolmax.